William J Jagust1, Susan M Landau2. 1. From the Helen Wills Neuroscience Institute, University of California, Berkeley; and Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA. jagust@berkeley.edu. 2. From the Helen Wills Neuroscience Institute, University of California, Berkeley; and Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA.
Abstract
OBJECTIVE: To understand the time course of β-amyloid (Aβ) deposition in the brain, which is crucial for planning therapeutic trials of Aβ-lowering therapies in Alzheimer disease (AD). METHODS: Two samples of participants from the Alzheimer's Disease Neuroimaging Initiative were studied with [18F]Florbetapir (FBP) Aβ PET and followed for up to 9 years. Sample A included 475 cognitively normal (CN) older people and those with mild cognitive impairment (MCI) and AD and sample B included 220 CN Aβ- individuals. We examined the trajectory of FBP over time in sample A and the incidence rate of conversion from negative to positive Aβ PET scans in sample B. RESULTS: The relationship between time and brain Aβ was sigmoidal, taking 6.4 years to transition from amyloid negative to positive and another 13.9 years to the onset of MCI. Aβ deposition rates began to slow only 3.8 years after reaching the positivity threshold. The incidence rate for scan positivity was 38/1,000 person-years, and factors associated with conversion were age, baseline FBP, and being a female APOE ε4 carrier. Among CN Aβ- individuals, FBP slopes were associated with rates of memory decline and brain tau measured with [18F]Flortaucipir PET 5 years after baseline. CONCLUSIONS: Lowering brain Aβ must be accomplished early in the evolution of AD. Transitions of PET scans from Aβ- to Aβ+ should be predictable, and it is reasonable to expect that lowering rates of Aβ even in early stages could produce clinically significant benefits.
OBJECTIVE: To understand the time course of β-amyloid (Aβ) deposition in the brain, which is crucial for planning therapeutic trials of Aβ-lowering therapies in Alzheimer disease (AD). METHODS: Two samples of participants from the Alzheimer's Disease Neuroimaging Initiative were studied with [18F]Florbetapir (FBP) Aβ PET and followed for up to 9 years. Sample A included 475 cognitively normal (CN) older people and those with mild cognitive impairment (MCI) and AD and sample B included 220 CN Aβ- individuals. We examined the trajectory of FBP over time in sample A and the incidence rate of conversion from negative to positive Aβ PET scans in sample B. RESULTS: The relationship between time and brain Aβ was sigmoidal, taking 6.4 years to transition from amyloid negative to positive and another 13.9 years to the onset of MCI. Aβ deposition rates began to slow only 3.8 years after reaching the positivity threshold. The incidence rate for scan positivity was 38/1,000 person-years, and factors associated with conversion were age, baseline FBP, and being a female APOE ε4 carrier. Among CN Aβ- individuals, FBP slopes were associated with rates of memory decline and brain tau measured with [18F]Flortaucipir PET 5 years after baseline. CONCLUSIONS: Lowering brain Aβ must be accomplished early in the evolution of AD. Transitions of PET scans from Aβ- to Aβ+ should be predictable, and it is reasonable to expect that lowering rates of Aβ even in early stages could produce clinically significant benefits.
Authors: Paul K Crane; Adam Carle; Laura E Gibbons; Philip Insel; R Scott Mackin; Alden Gross; Richard N Jones; Shubhabrata Mukherjee; S McKay Curtis; Danielle Harvey; Michael Weiner; Dan Mungas Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Scott C Neu; Judy Pa; Walter Kukull; Duane Beekly; Amanda Kuzma; Prabhakaran Gangadharan; Li-San Wang; Klaus Romero; Stephen P Arneric; Alberto Redolfi; Daniele Orlandi; Giovanni B Frisoni; Rhoda Au; Sherral Devine; Sanford Auerbach; Ana Espinosa; Mercè Boada; Agustín Ruiz; Sterling C Johnson; Rebecca Koscik; Jiun-Jie Wang; Wen-Chuin Hsu; Yao-Liang Chen; Arthur W Toga Journal: JAMA Neurol Date: 2017-10-01 Impact factor: 18.302
Authors: Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky Journal: J Nucl Med Date: 2012-02-13 Impact factor: 10.057
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; David S Knopman; Val Lowe; Prashanthi Vemuri; Michelle M Mielke; David T Jones; Matthew L Senjem; Jeffrey L Gunter; Brian E Gregg; Vernon S Pankratz; Ronald C Petersen Journal: Neurology Date: 2013-10-16 Impact factor: 9.910
Authors: Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Napatkamon Ayutyanont; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Hua Mo; Liliana Lopez; Sonia Moreno; Natalia Acosta-Baena; Margarita Giraldo; Gloria Garcia; Rebecca A Reiman; Matthew J Huentelman; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera; Eric M Reiman Journal: Lancet Neurol Date: 2012-11-06 Impact factor: 44.182
Authors: Suzanne E Schindler; Yan Li; Virginia D Buckles; Brian A Gordon; Tammie L S Benzinger; Guoqiao Wang; Dean Coble; William E Klunk; Anne M Fagan; David M Holtzman; Randall J Bateman; John C Morris; Chengjie Xiong Journal: Neurology Date: 2021-09-09 Impact factor: 11.800
Authors: Leonardo A Rivera-Rivera; Laura Eisenmenger; Karly A Cody; Thomas Reher; Tobey Betthauser; Robert V Cadman; Howard A Rowley; Cynthia M Carlsson; Nathaniel A Chin; Sterling C Johnson; Kevin M Johnson Journal: Alzheimers Dement (Amst) Date: 2021-12-31
Authors: Joseph Therriault; Tharick A Pascoal; Marcus Sefranek; Sulantha Mathotaarachchi; Andrea L Benedet; Mira Chamoun; Firoza Z Lussier; Cécile Tissot; Bruna Bellaver; Pamela S Lukasewicz; Eduardo R Zimmer; Paramita Saha-Chaudhuri; Serge Gauthier; Pedro Rosa-Neto Journal: Ann Clin Transl Neurol Date: 2021-10-07 Impact factor: 4.511
Authors: Jun Pyo Kim; Min Young Chun; Soo-Jong Kim; Hyemin Jang; Hee Jin Kim; Jee Hyang Jeong; Duk L Na; Sang Won Seo Journal: Front Aging Neurosci Date: 2022-02-07 Impact factor: 5.750
Authors: Hannes Devos; Kathleen Gustafson; Ke Liao; Pedram Ahmadnezhad; Bradley Estes; Laura E Martin; Jonathan D Mahnken; William M Brooks; Jeffrey M Burns Journal: Transl Neurodegener Date: 2022-02-09 Impact factor: 8.014
Authors: Daniel W Sirkis; Luke W Bonham; Taylor P Johnson; Renaud La Joie; Jennifer S Yokoyama Journal: Mol Psychiatry Date: 2022-04-07 Impact factor: 13.437
Authors: Alex C Birdsill; Rebecca L Koscik; Karly A Cody; Erin M Jonaitis; Robert V Cadman; Claire M Erickson; Nathaniel A Chin; Robert J Przybelski; Cynthia M Carlsson; Sanjay Asthana; Bradley T Christian; Laura B Eisenmenger; Tobey J Betthauser; Sterling C Johnson Journal: Alzheimers Dement (Amst) Date: 2022-09-20